Current Report Filing (8-k)
December 21 2020 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 15, 2020.
PLIANT THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-39303
|
|
47-4272481
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
260 Littlefield Avenue,
South San Francisco, CA
|
|
|
|
94080
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code: (650)
481-6770
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per share
|
|
PLRX
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.03
|
Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
On December 15, 2020, the Board of Directors of Pliant Therapeutics, Inc. (the Company) approved an amendment and restatement to the
Companys Amended and Restated Bylaws (the Bylaw Amendment), to designate the federal district courts of the United States of America as the sole and exclusive forum for resolving any action asserting a claim arising under the
Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.
The foregoing summary and
description of the provisions of the Bylaw Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaw Amendment, a copy of which is filed as Exhibit 3.1 with this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PLIANT THERAPEUTICS, INC.
|
|
|
|
|
Date: December 21, 2020
|
|
|
|
By:
|
|
/s/ Keith Cummings
|
|
|
|
|
|
|
Keith Cummings, M.D., MBA
|
|
|
|
|
|
|
Chief Financial Officer
|
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024